Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.85 [0.13, 5.61]
5 studies · 1734 participants
Low

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3899 participants
GRADE not reported

Stroke · 17,802 patients with low to normal levels of low density lipoprotein (LDL) cholesterol (< 130 mg/dL)

Statin probably leads to lower any stroke compared with placebo (moderate certainty).

1 finding from 1 review

Statins for primary prevention of venous thromboembolism 2014 · Cochrane Headline outcomes only
OR 0.51 [0.34, 0.78]
1 study · 17802 participants
Moderate